Generics Generated Over $200 Billion in Savings in 2017

As the nation grapples with ways to lower healthcare costs, access to generics plays a large role in saving patients, and the health system, money at the pharmacy counter. In 2017 alone, generics generated $265 billion in savings, according to a report from the Association for Accessible Medicines.

Savings for Medicare and Medicaid alone totaled $82.7 billion and $40.6 billion, respectively.

In 2017, generics accounted for 9 of every 10 prescriptions filled in the United States, and 93% of these prescriptions were filled at $20 or less. While brand name drugs accounted for just 10% of prescriptions, they were responsible for 77% of prescription spending. Due to high costs, those prescribed brand name drugs were 2 to 3 times more likely to not pick up their prescription after calling it in.

Looking by drug class, the biggest savings were seen in mental health, which saved $42 billion from generic drugs, followed by $34 billion for cholesterol and $31 billion for hypertension. By patient condition, savings totaled $48 billion for mental illness, $47 billion for heart disease, and $17 billion for epilepsy.

Savings by state averaged $5.2 billion, ranging from $354 million in Alaska to $23.2 billion in California.

In recent years, the gradual introduction of biosimilars to the market has provided another outlet for prescription cost savings. In the 8 years since the passage of the Biologics Price Competition and Innovation Act (BPCIA), 12 biosimilars have been approved, most recently a second biosimilar to Amgen’s reference filgrastim (Neupogen), used to treat neutropenia.


Recent Posts

See All

Administration’s radical actions on drug pricing

By Albert DiPiero MD, MPH Everyone is going after a common enemy these days: Big Pharma and high drug prices. The House and Senate have both stated that the days of unrelenting increases in drug price

The battle for inner peace and serenity

Two apps - “Headspace” and “Calm” - are in a fight to the death for control of the mindfulness market. They have a lot in common: “Both startups are venture-backed, founded by charismatic British guys